Q32 Bio (Q32 Bio) Short-Term Debt : $3.09 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Short-Term Debt?

Q32 Bio's Short-Term Debt for the quarter that ended in Mar. 2024 was $3.09 Mil.

Q32 Bio's quarterly Short-Term Debt declined from Sep. 2023 ($37.81 Mil) to Dec. 2023 ($0.88 Mil) but then increased from Dec. 2023 ($0.88 Mil) to Mar. 2024 ($3.09 Mil).

Q32 Bio's annual Short-Term Debt increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($32.40 Mil) but then declined from Dec. 2022 ($32.40 Mil) to Dec. 2023 ($0.88 Mil).

Q32 Bio Short-Term Debt Historical Data

The historical data trend for Q32 Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Short-Term Debt Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Debt

32.40

0.88

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial			32.40	-	37.81	0.88	3.09

Q32 Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Q32 Bio Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024